NewAmsterdam Pharma Company N.V.

Latest Results (09.10.2025):

NewAmsterdam Pharma Company N.V. reported its financial results for the third quarter of 2024, showcasing continued progress in its clinical trials and a strengthened financial position. The company highlighted significant advancements in its Phase 3 trials and maintained a robust cash reserve to support ongoing and future initiatives.

Clinical Trial Milestones

NewAmsterdam remains on track to release topline data from its pivotal Phase 3 TANDEM and BROADWAY trials in the fourth quarter of 2024, following faster-than-expected patient enrollment. These trials are critical in evaluating the efficacy of obicetrapib, both as a monotherapy and in combination with ezetimibe, for lowering LDL-C in patients with cardiovascular disease.

Strong Financial Position

The company reported a solid cash position of $422.7 million as of September 30, 2024, up from $340.5 million at the end of the previous year. This increase is primarily due to successful financing activities and the achievement of key clinical development milestones.

Revenue Growth

Revenue for the third quarter reached $29.1 million, a significant rise from $2.9 million in the same period last year. This growth was driven by a clinical development milestone achieved in collaboration with Menarini.

Expense Management

Research and Development expenses decreased to $35.7 million from $43.4 million year-over-year, mainly due to reduced clinical trial costs. However, Selling, General and Administrative expenses rose to $18.4 million from $9.1 million, reflecting increased personnel costs and investments to support the company’s growth and potential commercialization efforts.

Improved Net Loss

The net loss for the third quarter was $16.6 million, a reduction from $47.1 million in the same period last year. This improvement is attributed to increased revenues and effective cost management strategies.